Beta Blockers and Melanoma by Vojvodic, Aleksandra et al.
 
_______________________________________________________________________________________________________________________________ 
3110                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2019 Sep 30; 7(18):3110-3112. 
https://doi.org/10.3889/oamjms.2019.781 
eISSN: 1857-9655 
Global Dermatology 
 
 
  
 
Beta Blockers and Melanoma 
 
 
Aleksandra Vojvodic
1
, Petar Vojvodic
2
, Tatjana Vlaskovic-Jovicevic
2
, Goran Sijan
3
, Sanja Dimitrijevic
4
, Zorica Peric-Hajzler
5
, 
Dusica Matovic
5
, Uwe Wollina
6
, Michael Tirant
7
, Nguyen Van Thuong
8
, Massimo Fioranelli
9*
, Torello Lotti
10
 
 
1
Department of Dermatology and Venereology, Military Medical Academy, Belgrade, Serbia; 
2
Clinic for Psychiatric Disorders 
“Dr. Laza Lazarevic”, Belgrade, Serbia; 
3
Clinic for Plastic Surgery and Burns, Military Medical Academy, Belgrade, Serbia; 
4
Department of Gynecology, Military Medical Academy, Belgrade, Serbia; 
5
Military Medical Academy, Belgrade, Serbia; 
6
Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Dresden, Germany; 
7
University G. Marconi, 
Rome, Italy; 
8
Vietnam National Hospital of Dermatology and Venereology, Hanoi, Vietnam; 
9
Department of Nuclear Physics, 
Sub-nuclear and Radiation, G. Marconi University, Rome, Italy; 
10
Department of Dermatology, University of G. Marconi, 
Rome, Italy 
 
Citation: Vojvodic A, Vojvodic P, Vlaskovic-Jovicevic T, 
Sijan G, Dimitrijevic S, Peric-Hajzler Z, Matovic D, Wollina 
U, Tirant M, Thuong NV, Fioranelli M, Lotti T. Beta 
Blockers and Melanoma. Open Access Maced J Med Sci. 
2019 Sep 30; 7(18):3110-3112. 
https://doi.org/10.3889/oamjms.2019.781 
Keywords: Beta-blockers; Melanoma 
*Correspondence: Massimo Fioranelli. Department of 
Nuclear Physics, sub-nuclear and radiation, G. Marconi 
University, Rome, Italy. E-mail: 
massimo.fioranelli@gmail.com 
Received: 12-Jun-2019; Revised: 06-Jul-2019; 
Accepted: 07-Jul-2019; Online first: 30-Aug-2019 
Copyright: © 2019 Aleksandra Vojvodic, Petar Vojvodic, 
Tatjana Vlaskovic-Jovicevic, Goran Sijan, Sanja 
Dimitrijevic, Zorica Peric-Hajzler, Dusica Matovic, Uwe 
Wollina, Michael Tirant, Nguyen Van Thuong, Massimo 
Fioranelli, Torello Lotti. This is an open-access article 
distributed under the terms of the Creative Commons 
Attribution-NonCommercial 4.0 International License (CC 
BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
Abstract 
Understanding the mechanisms of cancer immune-tolerance is one of the most important challenges. Several 
studies have demonstrated the potential anticarcinogenic effects of beta-blockers, in patients with prostate 
cancer, breast cancer, and melanoma. At the other side variety of dermatoses may be caused or aggravated by 
β-blockers-psoriasis, lichen planus-like drug eruptions (LDE), acrocyanosis, alopecia etc.   Beta-blockers have 
been shown to improve the prognosis of melanoma patients significantly. Propranolol inhibits melanoma by 
downregulating the tumour angiogenesis but also tumour cell proliferation, invasiveness and local immune 
suppression. Studies showed that only β3-but, not β2-adrenoceptors, were up-regulated under hypoxia in 
peripheral blood mononuclear cells and selectively expressed in immune cell sub-populations including Treg, 
MDSC, and NK. They increased NK and CD8 number and cytotoxicity. Catecholamines may retard melanoma 
progression and that β-blockers may have unrecognised potential as a therapeutic intervention for melanoma, in 
the prevention of the growth of melanoma in all stages and as adjuvant therapy with other targeted and immune 
therapies for melanoma. 
 
 
 
 
 
 
 
 
Introduction 
 
Understanding the mechanisms of cancer 
immune-tolerance is one of the most important 
challenges. Melanoma is one of the most aggressive 
tumours. Metastatic melanoma remains a significant 
clinical problem, with five-year survival rates of only 
15–20%. It is well known that stress-related 
catecholamines have a role in cancer and β-
adrenoceptors. β2-adrenoceptors have been identified 
as new targets in treating melanoma.  
Recent studies showed β3-adrenoceptors 
have a pleiotropic effect on melanoma 
microenvironment leading to cancer progression, but 
the mechanisms are poorly understood. β-Blockers 
are one of the most widely used therapeutic agents in 
both cardiac and non-cardiac ailments, but also, have 
garnered interest amongst dermatologists based on 
the discovery of their demonstrated and potential 
effects in disorders such as pyogenic granulomas, 
vascular malformations, erythematous-telangiectatic 
rosacea and wound healing.  
Several studies have demonstrated the 
potential anticarcinogenic effects of beta-blockers, in 
patients with prostate cancer, breast cancer, and 
melanoma. At the other side variety of dermatoses 
may be caused or aggravated by β-blockers-psoriasis, 
lichen planus-like drug eruptions (LDE), acrocyanosis, 
alopecia etc.  
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Discussion 
 
The use of β-blockers in patients with 
melanoma for the first time was published by De 
Giorgi et al. A median follow-up of 2.5 years, 34% of 
patients not using β-blockers had evidence of disease 
progression, while only 3% of those who used β-
blockers (for other diseases) at the time of diagnosis 
showed melanoma progression. 
Psychosocial factors as chronic stress and 
depression and anxiety are listed as risk factors for 
cancer onset and progression.  
Under conditions of reduced physiological 
stress, the T cell-dependent anti-tumour immune 
response is greatly enhanced. These findings suggest 
that targeting the βAR signalling pathway directly to 
reduce stress signalling may provide an innovative 
approach to improve cancer treatment. 
Beta-blockers have been shown to improve 
the prognosis of melanoma patients significantly. 
Propranolol inhibits melanoma by downregulating the 
tumour angiogenesis but also tumour cell proliferation, 
invasiveness and local immune suppression Calvani 
et all in their studies showed that only β3-but not β2-
adrenoceptors, were up-regulated under hypoxia in 
peripheral blood mononuclear cells and selectively 
expressed in immune cell sub-populations including 
Treg, MDSC, and NK. They increased NK and CD8 
number and cytotoxicity. 
There are several studies with results support 
previous observation that β-blockers protect patients 
with thick cutaneous melanoma from disease 
recurrence and death. In one of them, after only 3 
years of treatment, disease progression was observed 
in 41.2% of the patients in the untreated cohort 
compared with only 15.8% in the propranolol cohort. 
Overall survival, although not significant, showed a 
trend toward decreased mortality in the propranolol 
group after 3 years of follow-up. 
Observational studies have reported the 
protective effect of β-blockers on the progression of 
different types of cancers. In total, 25% of them 
reported previous use of β-blockers that were 
administered at any time for any other diseases. After 
a median follow-up of 2.5 years, 34% of the patients in 
the untreated group showed disease progression. In 
contrast, only 3% of the patients in the treated group 
showed progression. After a median follow-up of 8 
years and a median duration of β-blocker use of 7.6 
years, 45% of the patients in the untreated group and 
30% of the patients in the treated group showed 
disease progression. Notably, in the untreated group, 
35% of patients died from melanoma, and only 17% of 
patients died from melanoma in the treated group. 
Results of this hospital-based prospective cohort 
study with a median follow-up of 8 years confirmed 
our previous results that the use of β-
blockers significantly reduced the risk of  
Propranolol treatment in the MT/Ret mouse 
model of melanoma delayed primary tumour growth 
and metastases development in MT/Ret mice. 
Propranolol induces a decrease in cell proliferation, 
and vessel density in the primary tumours and 
metastases and propranolol significantly reduced the 
infiltration of myeloid cells, particularly neutrophils, in 
the primary tumour. Cytotoxic tumour-infiltrating 
lymphocytes were more frequent in the tumour stroma 
of treated mice 
It is conceivable that a therapeutic approach 
targeting the beta-adrenergic system could constitute 
a novel and promising strategy 
for melanoma treatment. 
In one study daily treatment with propranolol 
slows down tumour development in immunodeficient 
mice transplanted with human melanoma cells, with 
the conclusion that non-cardioselective β-
blockers affect melanoma progression, and bring first 
clues about the pathways involved in this antitumor 
effect. 
In conclusion, randomised clinical studies are 
necessary (the type of β-blocker, characteristics of the 
tumour, appropriate treatment and efficacy) before β-
blockers can be considered a therapeutic option for 
patients with melanoma. But so far, the observations 
described suggest that catecholamines may 
retard melanoma progression and that β-blockers may 
have unrecognised potential as a therapeutic 
intervention for melanoma, in the prevention of the 
growth of melanoma in all stages and as adjuvant 
therapy with other targeted and immune therapies for 
melanoma.  
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